RVL Pharmaceuticals plc
RVLPQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$110.18M
Close$
Share Statistics
| Market cap | $110.18 Million |
|---|---|
| Enterprise Value | $150.22 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.58 |
| Beta | 8.8 |
| Outstanding Shares | 99,370,291 |
Return
| Return on Equity | -418.14% |
|---|---|
| Return on Assets | -79.93% |
| Return on Invested Capital | -253.94% |
Valuation & Multiples
| P/E Ratio | -0.05 |
|---|---|
| PEG | -0.05 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 4.07 |
| Enterprise Value to EBIT | -3.48 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.39 |
| Debt to Equity | 3.63 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
$-0.23
Average shareholder expectationRevenue Estimate
$30.65 M
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-0.23
Average shareholder expectationRevenue Estimate
$30.65 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Osmotica Pharmaceuticals Plc
125 employees
CEO: Brian A. Markison RVL Pharmaceuticals plc operates as a specialized drug company, dedicated to innovating and marketing pharmaceutical solutions for patient groups with unmet needs in the ophthalmic and medical aesthetics domains. The firm's activities ex...